- Oops!Something went wrong.Please try again later.
Shares of Reata Pharmaceuticals (NASDAQ:RETA) rose 17.5% in pre-market trading after the company reported Q3 results.
Earnings per share were up 0.76% over the past year to ($1.31), which beat the estimate of ($1.98).
Revenue of $1,401,000 declined by 83.00% year over year, which beat the estimate of $1,270,000.
Reata Pharmaceuticals hasn't issued any earnings guidance for the time being.
Reata Pharmaceuticals hasn't issued any revenue guidance for the time being.
How To Listen To The Conference Call
Date: Nov 09, 2020
Time: 08:30 AM
ET Webcast URL: https://edge.media-server.com/mmc/p/z6fgbcwf
Company's 52-week high was at $257.96
Company's 52-week low was at $88.17
Price action over last quarter: Up 49.61%
Reata Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing therapeutics to address serious and life-threatening diseases by targeting molecular pathways. The company's product in the pipeline include bardoxolone methyl; Omaveloxolone and others.
See more from Benzinga
© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.